Drug intelligence / Profile preview

GT0007X

Development stage: Preclinical
Lead developer: ONODERA GT Pharma
Modality: Gene Therapies
Administration: Intrathecal

Overview

GT0007X is a preclinical-stage adeno-associated virus (AAV) gene therapy candidate developed by ONODERA GT Pharma for the treatment of Alzheimer's disease. The therapy utilizes an AAV vector to deliver a therapeutic genetic payload to the central nervous system, aiming to modify the disease course or alleviate symptoms of dementia. As of 2024, the specific molecular target and transgene for GT0007X have not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on GT0007X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT0007X.

Explore the full profile